Cargando…
PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
The aim of the present study was to establish a physiologically based pharmacokinetic (PBPK) model for coproporphyrin I (CP‐I), a biomarker supporting the prediction of drug‐drug interactions (DDIs) involving hepatic organic anion transporting polypeptide 1B (OATP1B), using clinical DDI data with an...
Autores principales: | Yoshikado, Takashi, Toshimoto, Kota, Maeda, Kazuya, Kusuhara, Hiroyuki, Kimoto, Emi, Rodrigues, A. David, Chiba, Koji, Sugiyama, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263667/ https://www.ncbi.nlm.nih.gov/pubmed/30175555 http://dx.doi.org/10.1002/psp4.12348 |
Ejemplares similares
-
Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies
por: Yoshikado, Takashi, et al.
Publicado: (2022) -
Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022) -
Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine
por: Jang, Yeonseo, et al.
Publicado: (2023) -
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023) -
Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020)